Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 8/20 | 0.46 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679180 | 0.92 | CA12 (0.44) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL4672642 | 0.90 | CA12 (0.43) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL4678500 | 0.90 | CA12 (0.44) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL5899386 | 0.90 | CA12 (0.43) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL4673345 | 0.89 | CA12 (0.41) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL4674739 | 0.89 | CA12 (0.43) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL4674047 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL4672591 | 0.86 | CA12 (0.42) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL4671557 | 0.85 | LMNA (0.39) | CA12CA1CA2CA9LMNA | |
| SCHEMBL4677818 | 0.83 | POLB (0.48) | CA12CA1CA2CA9CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1142872-B1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6645956-B1 | 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment | SHIONOGI & CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6620841-B1 | Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) | SHIONOGI & CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| US-20030171406-A1 | Medicinal compositions containing propenone derivatives | SHIONOGI & CO., LTD (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1295879-A1 | MEDICINAL COMPOSITIONS CONTAINING PROPENONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| CN-1335834-A | Aromatic heterocyclic compounds having HIV integrase inhibitory activity | SHIONOGI & CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | CA12 4245/4885CA1 3590/4885CA2 2384/4885 |
| US-20030171406-A1 | Medicinal compositions containing propenone derivatives | RPL17, EBP, SERPINB1 | CA12 4013/4885CA1 3634/4885CA2 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.